Elevated serum MIF levels in NSCLC predict worse overall and progression-free survival, and co-expression with CD74 correlates strongly with enrichment of tumor-associated CXC chemokines and tumor vascularization [147,148]. Here, MIF is linked to non-small cell lung carcinoma.